Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) EBIT (2020 - 2025)

Vivos Therapeutics has reported EBIT over the past 6 years, most recently at -$6.4 million for Q4 2025.

  • Quarterly EBIT fell 127.44% to -$6.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$19.9 million through Dec 2025, down 78.11% year-over-year, with the annual reading at -$19.9 million for FY2025, 78.09% down from the prior year.
  • EBIT was -$6.4 million for Q4 2025 at Vivos Therapeutics, down from -$4.7 million in the prior quarter.
  • Over five years, EBIT peaked at $8.7 million in Q4 2021 and troughed at -$7.0 million in Q2 2022.
  • The 5-year median for EBIT is -$4.3 million (2023), against an average of -$3.9 million.
  • The largest YoY upside for EBIT was 239.41% in 2021 against a maximum downside of 202.83% in 2021.
  • A 5-year view of EBIT shows it stood at $8.7 million in 2021, then tumbled by 169.61% to -$6.1 million in 2022, then skyrocketed by 31.83% to -$4.1 million in 2023, then soared by 32.11% to -$2.8 million in 2024, then plummeted by 127.44% to -$6.4 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's EBIT are -$6.4 million (Q4 2025), -$4.7 million (Q3 2025), and -$4.9 million (Q2 2025).